First-line Combination Therapy for BRAF-mutated Metastatic Colorectal Cancer
The FDA approved the kinase inhibitors encorafenib and cetuximab plus chemotherapy for the treatment of certain colorectal cancers. The...
Progress Against Cancer
The FDA approved the kinase inhibitors encorafenib and cetuximab plus chemotherapy for the treatment of certain colorectal cancers. The...
The FDA approved the mesenchymal stromal cell therapy remestemcel-L-rknd for some pediatric patients as young as 2 months. ...
The FDA approved ensartinib for certain patients with locally advanced or metastatic non-small cell lung cancer. The U.S. Food...
The FDA approved cosibelimab-ipdl for certain skin cancers that cannot be treated with surgery or radiation. The U.S. Food...
The FDA approved durvalumab for some patients with previously treated limited-stage small cell lung cancer. The U.S. Food...
The FDA approved the targeted therapy zenocutuzumab-zbco for certain patients with lung or pancreatic cancer. The U.S. Food and...
The FDA granted accelerated approval to the first-in-class HER2-directed bispecific antibody zanidatamab-hrii. The U.S. Food and Drug Administration (FDA)...
The FDA Project Renewal initiative has updated the approved indications for fludarabine phosphate chemotherapy in chronic lymphocytic leukemia. The...
The FDA approved revumenib, a first-in-class menin inhibitor, to treat acute leukemias with a KMT2A translocation. The U.S. Food...
The cell-based immunotherapy was approved for adults with relapsed or refractory acute lymphoblastic leukemia. The U.S. Food and Drug...